Results 101 to 110 of about 5,134 (265)

A Comparison of Oral Dydrogesterone with Vaginal Progesterone for Luteal-Phase Support in In vitro Fertilization: A Randomized Controlled Trial

Advanced Biomedical Research, 2023
Background: The quality of the luteal phase is the most important issue affecting pregnancy outcomes in assisted reproductive technology (ART). Luteal-phase support with the administration of gonadotropin-releasing hormone (GnRH) agonist or progesterone ...
E. Naghshineh, Hatav Ghasemi Tehrani, F. Sharifian, Somayeh Haghighat   +3 more
semanticscholar   +1 more source

Tools for clinical pharmacists to identify medications that can cause drug‐induced cognitive impairment: A systematic review

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 7, Issue 12, Page 1207-1227, December 2024.
Abstract Cognitive impairment affects around 19% of community‐dwelling older adults in the United States. Pharmacists can play a significant role in identifying and deprescribing cognitive‐impairing medications through cognitive‐focused medication reviews or as part of comprehensive medication management.
Jacob Stanton, Michael R. Gionfriddo, Gail B. Rattinger, Yuan Fang, Mia E. Lussier   +4 more
wiley   +1 more source

Micronised vaginal progesterone versus oral dydrogestrone in the treatment of dysfunctional uterine bleeding: efficacy and effects on lipid profile

Cukurova Medical Journal, 2021
Purpose: The aim of this study was to compare the efficacy of short-course oral dydrogesterone versus vaginal micronized progesterone and to determine their effects on the lipid profile of the premenopausal women with dysfunctional uterine bleeding ...
Alev Özer, Abdullah Tok, Gülcan Akdemir, Gürkan Kıran   +3 more
doaj  

Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism

Clinical Endocrinology, Volume 101, Issue 5, Page 409-442, November 2024.
Abstract Female hypogonadism (FH) is a relatively common endocrine disorder in women of premenopausal age, but there are significant uncertainties and wide variation in its management. Most current guidelines are monospecialty and only address premature ovarian insufficiency (POI); some allude to management in very brief and general terms, and most ...
Channa N. Jayasena, Kerri Devine, Katie Barber, Alexander N. Comninos, Gerard S. Conway, Anna Crown, Melanie C. Davies, Ann Ewart, Leighton J. Seal, Arlene Smyth, Helen E. Turner, Lisa Webber, Richard A. Anderson, Richard Quinton   +13 more
wiley   +1 more source

Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-blind, placebo-controlled trial.

Journal of Maternal-Fetal & Neonatal Medicine
OBJECTIVE To determine the effectiveness of oral dydrogesterone in preventing miscarriage in threatened miscarriage. METHODS A randomized, controlled trial study was conducted among pregnant Thai women at the gestational age of six to less than 20 ...
Arissara Kuptarak, V. Phupong
semanticscholar   +1 more source

Comparison of progestin‐primed ovarian stimulation regimen and antagonist regimen in women aged 35 years or older with diminished ovarian reserve: A propensity score‐matched study

International Journal of Gynecology &Obstetrics, Volume 167, Issue 1, Page 162-168, October 2024.
Abstract Objective Diminished ovarian reserve (DOR) has been a major challenge in infertility treatment. The present study aimed to compare the efficacy of progestin‐primed ovarian stimulation (PPOS) regimen and antagonist regimen in infertile patients aged 35 years or older with DOR.
Mohan Wang, Linlin Li, Haibo Zhu, Ruixue Wang, Ruizhi Liu, Han Zhang   +5 more
wiley   +1 more source

Menopausal hormone therapy and venous thromboembolism

Menopause Review, 2014
Menopausal hormone therapy (MHT) is the most effective method of treating vasomotor symptoms and other climacteric symptoms related to estrogen deficiency in peri- and postmenopausal period.
Małgorzata Bińkowska
doaj   +1 more source

Treatment of symptoms of the menopause: an endocrine society clinical practice guideline [PDF]

, 2015
Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Murad, M. Hassan, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +6 more
core   +1 more source

Australasian recurrent pregnancy loss clinical management guideline 2024, part II

Australian and New Zealand Journal of Obstetrics and Gynaecology, Volume 64, Issue 5, Page 445-458, October 2024.
Part II of the Australasian guideline for the investigation and management of recurrent pregnancy loss (RPL) provides evidence‐based guidance on the management of RPL provided. The implications of inherited and acquired thrombophilia with respect to RPL and suggestions for clinical management are provided.
Adriana SUKER, Ying LI, Danielle ROBSON, Anthony MARREN, the Australasian CREI (Certificate of Reproductive Endocrinology and Infertility) Consensus Expert Panel on Trial Evidence (ACCEPT) Group, Rob Norman, Gab Kovacs, Lucy Prentice, Elizabeth Glanville, Leigh Searle, Olivia Stuart, Vicki Nisenblat, Neil Johnson, Yousif Alyousif, Maree Lee, Kate Burston, Michael Chapman, L Sebastian, Phill McChessney, Clare Boothroyd, Neerja Kamal, Anne Clark, Violet Kieu, Rituparna Dutta, Lynn Burmeister, Ashleigh Smith, Louise Hull, Vamsee Thalluri, Giselle Crawford, Beverley Vollenhoven Sarah Hunt, Nicole Hope, Sameer Jakar, Seema Mohiuddin, Fleur Cattrall, Peter Leung, Roger Hart, Alison Gee, Katrina Rowan, Michele Kwik, Iris Wang, Jinny Foo, Rabia Shaik, Tamara Hunter, Nalini Gayer, Raelia Lew, Rebecca Mackenzie‐Proctor, Anusch Yazdani, Rob Lahoud, Cheryl Phua, Shannon Zawada, Gabrielle Dezarnaulds, Sonal Karia, Devini Ameratunga, Vanessa Ross, Manny Mangat, Raewyn Tierney, Shadi Khashaba, David Greening, Janelle McDonald, Myvanwy McAveen   +59 more
wiley   +1 more source

Progestogen hypersensitivity: successful use of progesterone desensitisation and omalizumab to facilitate in vitro fertilisation

Internal Medicine Journal, Volume 54, Issue 10, Page 1749-1752, October 2024.
Abstract Hypersensitivity to exogenous or endogenous progesterone presents with a variety of clinical, usually cutaneous, manifestations. The condition can occur at any age during the reproductive years, causes debilitating symptoms and can impact the use of exogenous hormones.
Gary Xu, Ramon Yuson, Martina Rafferty, Thuy L. Thai, Sandhya Limaye   +4 more
wiley   +1 more source